Scuba, Congratulations! Please post the last few PCR results verbatim minus the HIPAA stuff. I would like to see how they construct the PCR results.
Note the results are in M.D. Anderson Scale not I.S. Scale. Note the "zero's" in parenthesis. I'm told this
is interpreted as below the limit of the technique (hence <0.01).
Dr. Cortes told me as long as I stay below 0.28 (which is 0.1 on the I.S. scale), he's fine with me doing what I am doing.
Below is the report:
MOLECULAR STUDY, PB RECEIVED
Other tests ordered on the same accession number are available below.
_____________________________________________
REAL TIME BCR, PB
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
BCR-ABL Quantitative PCR PB <0.0100 % (0.0000- 0.0000)
Low Positive is < 0.01 BCR-ABL to ABL transcipts
High Positive is > 100.00 BCR-ABL to ABL transcipts
REAL TIME BCR INTERP PB
t(9;22); BCR-ABL1 Translocation Assay by Quantitative RT-PCR:
A b2a2 BCR-ABL1 fusion transcript coding for the 210kDa BCR-ABL1 fusion
protein is detected by quantitative real-time RT-PCR.
The percentage of BCR-ABL1 to ABL1 transcripts is <0.01.
Methodology:
Quantitative real-time PCR analysis was performed on reverse-transcribed
RNA from this sample for the BCR-ABL1 fusion transcripts resulting from
the t(9;22)(q34;q11.2) in Leukemia. This multiplex assay is designed to
detect common BCR-ABL1 fusion transcripts e13a2(b2a2), e14a2(b3a2) and
e1a2. The fusion transcripts are differentiated based on the size of the
PCR product using capillary electrophoresis. BCR-ABL1 and ABL1 transcript
levels are detected simultaneously and quantitative results are expressed
as the percent ratio of BCR-ABL1 to ABL1 transcript levels. This ratio
may vary up to one-log because of methodological reasons. The sensitivity
of detection of BCR-ABL1 transcripts by real-time PCR is between 1 in
10,000 and 1 in 100,000
Comment:
This assay can be used to monitor minimal residual disease (MRD).
ASR Disclaimer:
This test was developed and its performance characteristics determined by
the Molecular Diagnostics Laboratory (MDL) at MD Anderson Cancer Center.
It has not been cleared or approved by the U.S. Food and Drug
Administration (FDA). The FDA has determined that such clearance or
approval is not necessary. This test is used for clinical purposes. This
laboratory is certified under the Clinical Laboratory Improvement Act
(CLIA) of 1988 to perform high complexity clinical laboratory testing.
++++++++++++++++++++++++++++++end report++++++++++++++++++++++++++++++++++++
February:
BCR-ABL Quantitative PCR PB <0.0100 % (0.0000- 0.0000)
March:
BCR-ABL Quantitative PCR PB <0.0100 % (0.0030- 0.0000)
April:
BCR-ABL Quantitative PCR PB <0.0100 % (0.0000- 0.0000)
May:
BCR-ABL Quantitative PCR PB <0.0100 % (0.0030- 0.0000)
June:
BCR-ABL Quantitative PCR PB <0.0100 % (0.0000- 0.0000)
Diagnosed 11 May 2011 (100% FiSH, 155% PCR)
with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein
Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate
6-8 grams Curcumin C3 complex.
2015 PCR: < 0.01% (M.D. Anderson scale)
2016 PCR: < 0.01% (M.D. Anderson scale)
March 2017 PCR: 0.01% (M.D. Anderson scale)
June 2017 PCR: "undetected"
September 2017 PCR: "undetected"